Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd. (QNRX): 11 pipeline candidates · 3 upcoming catalysts · ~9 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.6 months
D/E 0.79 · 0% dilution
Lead: Approved
11 candidates
3 upcoming, next in ~42d
N/A
A transparent, data-derived signal for Quoin Pharmaceuticals, Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.4M
Cash
$3.1M
Quarterly Burn
$4.9M
Runway
8.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| qrx003 | Phase 2/Phase 3 |
| qrx003-2% lotion | Phase 2/Phase 3 |
| qrx003-4% lotion bid | Phase 2/Phase 3 |
| qrx003-4% lotion qam | Phase 2/Phase 3 |
| qrx004 | Phase 2/Phase 3 |
| qrx007 | Phase 2/Phase 3 |
| qrx008 | Phase 2/Phase 3 |
| qrx009 | Phase 2/Phase 3 |
| treatments or cures | Approved |
| treatments or cures | Approved |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$2.7M
| Holder | Shares | Value |
|---|---|---|
| summittx capital, l.p. | 100,300 | $662K |
| millennium management llc | 76,247 | $503K |
| boothbay fund management, llc | 59,838 | $395K |
| stonepine capital management, llc | 53,460 | $353K |
| aigh capital management llc | 51,000 | $337K |
| citadel advisors llc | 32,519 | $215K |
| birchview capital, lp | 20,000 | $132K |
| morgan stanley | 4,000 | $26K |
| ubs group ag | 2,512 | $17K |
| gamma investing llc | 1,720 | $11K |
Showing top 10 of 14 institutional holders of Quoin Pharmaceuticals, Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Quoin Pharmaceuticals, Ltd.'s pipeline?
Quoin Pharmaceuticals, Ltd. (QNRX) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Quoin Pharmaceuticals, Ltd.'s lead drug candidate?
Quoin Pharmaceuticals, Ltd.'s most advanced tracked candidate is qrx003 (Phase 2/Phase 3) for Netherton Syndrome.
What is Quoin Pharmaceuticals, Ltd.'s next catalyst?
Quoin Pharmaceuticals, Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndr" — expected July 30, 2026.
What is Quoin Pharmaceuticals, Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Quoin Pharmaceuticals, Ltd. has approximately 8.6 months of cash runway.
What is Quoin Pharmaceuticals, Ltd.'s market capitalization?
Quoin Pharmaceuticals, Ltd.'s market capitalization is approximately $8.4M.
Get the full picture on Quoin Pharmaceuticals, Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.